STAT+: Genetics may shape GLP-1 outcomes, slightly

A genome-wide association study published in Nature on April 8, 2026 put real numbers on something clinicians have suspected for years. The 23andMe Research Institute analyzed 27,885 consented participants who had used GLP-1 medications and identified variants in two genes — GLP1R and GIPR — that predict, with modest accuracy, how much weight someone will lose and how likely they are to develop nausea or vomiting. Estimated weight loss across the cohort ranged from 6% to over 20% of baseline body weight. Nausea probability ranged from 5% to 78%. The GLP1R missense variant most strongly linked to weight loss was quantified: carrying one copy added roughly 1.7 extra pounds lost over eight months; two copies added about 3.3 pounds.

The drug-specific finding is where the data gets clinically interesting. The GIPR gene variant’s association with nausea and vomiting appeared specifically in tirzepatide users — not semaglutide users. That makes biological sense, since tirzepatide (Zepbound/Mounjaro) targets both GLP-1 and GIP receptors, while semaglutide only hits GLP-1. If you’re prone to nausea on tirzepatide, there’s now a plausible genetic explanation — and it hints at a future where receptor-specific genetic data helps guide which drug a patient starts on. 23andMe plans to deliver these findings directly to members through a new “GLP-1 Medications: Weight Loss and Nausea” report available via its Total Health platform.

Here’s the important caveat: outside researchers consistently described the effect as real but modest — not clinically actionable yet. The study population skews white and female, which limits how well these results translate across diverse populations. Genetics explains some of the variation in outcomes, but dose titration, diet quality, insulin resistance, starting BMI, and adherence explain more. A genetic signal of 1.7–3.3 extra pounds across eight months sits well below the noise of any individual’s week-to-week variation on these medications.

What to watch: this study was observational, not a randomized intervention. The next step that would actually matter to your prescriber is a trial where genetic data prospectively guides drug selection, then measures whether outcomes improve. No such trial is currently underway. Until one reads out, treat this as science-in-progress rather than a tool for your next doctor’s appointment. If personalized GLP-1 prescribing based on genetics ever becomes clinical practice, the realistic timeline is the early 2030s at the earliest.

Frequently Asked Questions

Which specific variants were found to predict GLP-1 weight loss and side effects?

The study identified a missense variant in the GLP1R gene associated with greater weight loss efficacy — about 1.7 extra pounds per copy over eight months. Variants in both GLP1R and GIPR were linked to nausea and vomiting risk. The GIPR variant’s side-effect association was specific to tirzepatide users, consistent with tirzepatide’s dual GLP-1/GIP mechanism. Neither variant is rare; both are common enough in the general population to be potentially relevant for many patients currently on these drugs.

Should I test my genetics before choosing between semaglutide and tirzepatide?

Not based on current evidence. No clinical guideline recommends genetic screening before starting a GLP-1. The gene variants identified are associated with outcome differences, but the effect sizes are too small to reliably predict whether you personally respond better to one drug than another. What your prescriber actually needs is your A1C, weight history, side effect tolerance, and insurance coverage — not a genetic report. If you already have 23andMe Total Health access, the new report is interesting context, but it’s not a prescribing tool.

Does this research explain why some patients see almost no weight loss on GLP-1s?

Partially, but genetics is a minor contributor. Weight loss on GLP-1s ranges enormously (6% to 20%+ in this study), and while GLP1R variants explain some variance, the bigger drivers are dose (many patients underdose to avoid nausea), diet composition, sleep quality, and adherence. If you’ve seen poor results, the conversation to have with your provider is about dose optimization and support systems — not genetic explanations. The study is clear: genetics adds a signal, not a verdict.

---

Keep Reading

• Semaglutide vs Tirzepatide: Clinical Comparison
• Wegovy: Full Medication Profile
• Zepbound: Full Medication Profile
• GLP-1 Eligibility Quiz: Check Your Profile